Our findings of the association of serum IFN activity with cutaneous manifestations are in agreement with the observation that the severity of cutaneous lesions positively correlated with IIG expression levels in PBMCs in SLE patients [38]. This evidence concerns the gene IFNA1 and systemic lupus erythematosus.